State College, PA -- June 23, 2003 -- The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) has invested close to $1 million in two promising biotechnology startup companies headquartered in State College, PA. NanoHorizons, Inc., a developer and producer of state-of-the-art nanotechnology products and processes, receive $500,000. QuantumBio, Inc., a software company that seeks to accelerate drug discovery efforts using unique molecular modeling tools, received $425,000. These represent the first of LSGPA's pre-seed stage investments, which are expected to total roughly $10 million over five years. Additionally, the companies received matching fund commitments exceeding $4 million.

From left to right: Mel Billingsley, President & CEO of the Life Sciences Greenhouse of Central PA; Dennis Yablonsky, Secretary PA Department of Community and Economic Development; Lance Westerhoff, Chief Software Engineer of QuantumBio, Inc.; Kenneth Merz, CEO of QuantumBio; Walter Greenblatt, CFO of QunatumBio; and Kevin Harter, Senior V.P. Business Development of the Life Sciences Greenhouse of Central PA

About QuantumBio, Inc.
QuantumBio's software suite of quantum mechanically-based molecular modeling tools and unique database of protein structures critical to drug discovery are based on technology developed between 1995 and the present at Penn State University (PSU) in the labs of Dr. Kenneth Merz, an international leader in the field of computational chemistry for drug discovery. These proprietary tools will enable scientists engaged in drug discovery to leverage the precision of quantum mechanical approaches to model interactions between proteins and small molecules far better than the classical mechanics-based software models currently available on the market. In addition, the company is expected to benefit from an expanding list of technology emerging from PSU in the form of provisional patents and invention disclosures.

State College, PA — June 18, 2003 — QuantumBio Inc., pioneering a next generation of Computer-Assisted Molecular Modeling (CAMM) and Computer-Assisted Drug Design (CADD) tools was awarded a technology grant from Ben Franklin Technology PArtners of Pennsylvania.

Ben Franklin Technology PArtners (BFTP) is a Commonwealth of Pennsylvania program established to foster innovation and economic growth. Established in 1983, BFTP provides capital to support the development of promising products and technologies by Pennsylvania-based companies.

QuantumBio received the BFTP grant to support the expanded development of proprietary technology developed by QuantumBio to model the complex quantum mechanically-based molecular modeling tools and unique database of protein structures critical to drug discovery. These proprietary tools will enable scientists engaged in drug discovery to leverage the precision of quantum mechanical approaches to model interactions between proteins and small molecules far better than the classical mechanics-based software models currently available on the market.

About Ben Franklin Technology Partners

For more than two decades, Ben Franklin Technology Partners, an international model for innovation in technology-based economic development, has worked to diversify and strengthen Pennsylvania’s economy by focusing on entrepreneurial development and technological innovation. BFTP delivers resources for technology-driven enterprises in sectors such as information technology, life sciences, communications, advanced manufacturing, advanced materials and environmental technology.

About QuantumBio, Inc.

QuantumBio's software suite of quantum mechanically-based molecular modeling tools and unique database of protein structures critical to drug discovery are based on technology developed between 1995 and the present at Penn State University (PSU) in the labs of Dr. Kenneth Merz, an international leader in the field of computational chemistry for drug discovery. These proprietary tools will enable scientists engaged in drug discovery to leverage the precision of quantum mechanical approaches to model interactions between proteins and small molecules far better than the classical mechanics-based software models currently available on the market. In addition, the company is expected to benefit from an expanding list of technology emerging from PSU in the form of provisional patents and invention disclosures.